Amylyx Pharmaceuticals
AMLX
110 hedge funds and large institutions have $141M invested in Amylyx Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 36 reducing their positions, and 31 closing their positions.
70% more capital invested
Capital invested by funds: $82.9M → $141M (+$57.8M)
0.34% less ownership
Funds ownership: 64.16% → 63.82% (-0.34%)
8% less funds holding
Funds holding: 119 → 110 (-9)
11% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 36
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
74% less call options, than puts
Call options by funds: $796K | Put options by funds: $3.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$10.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$4.78M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$4.17M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.16M |
| 5 |
AWG
Alpha Wave Global
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$6.05M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$2.85M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.55M |
| 4 |
Millennium Management
New York
|
-$2.42M |
| 5 |
Goldman Sachs
New York
|
-$2.24M |
AMLX Hedge Fund Activity: Q3 2024 in Review
110 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q3 2024, worth a combined $141M — up 70% from $82.9M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AMLX and 22 opened new positions — a net loss of 9 holders — while 36 trimmed existing stakes and 32 added.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $10.4M. The largest seller was AQR Capital Management, cutting an estimated $6.05M.
- 110 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q3 2024, down from 119 in Q2 2024.
- Funds reported $141M of Amylyx Pharmaceuticals stock for Q3 2024, up 70% quarter-over-quarter.
- 22 funds opened new Amylyx Pharmaceuticals positions in Q3 2024 and 31 closed out, a net change of -9 holders.
- The largest Amylyx Pharmaceuticals buyer in Q3 2024 was TCG Crossover Management, an estimated $10.4M added.
- The largest Amylyx Pharmaceuticals seller in Q3 2024 was AQR Capital Management, an estimated $6.05M sold.
Based on aggregated 13F filings for Q3 2024.